Fennec Pharmaceuticals (FENC)
Commercializes PEDMARK for pediatric cisplatin-related hearing-loss protection.
Something off on this page? Send us feedback.
Sells PEDMARK in the United States and receives economics from PEDMARQSI outside the United States through Norgine. The business runs as one segment around sodium thiosulfate for children with localized, non-metastatic solid tumors receiving cisplatin.
Commercializes PEDMARK in the United States, where the product is approved to reduce cisplatin-associated hearing-loss risk in pediatric patients with localized, non-metastatic solid tumors. PEDMARQSI is the ex-U.S. brand for the same sodium thiosulfate franchise.
Works through a narrow specialty-pharma model from Research Triangle Park. The company reports one operating segment, and opened context describes its commercial identity around PEDMARK awareness, access support, and provider education.
Relies on one franchise for foreseeable product revenue. Outside the United States, Norgine leads PEDMARQSI commercialization in licensed territories, while a Cipla settlement shapes potential U.S. generic timing through 2033 except under specified circumstances.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 12, 2026 | Wedbush | Reiterate | Outperform | $19 | $16 |
| May 22, 2026 | H.C. Wainwright | Target | $15 | $16 | |
| Jan 8, 2026 | Piper Sandler | Target | $18 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $41.2M · Total debt $0 · Total assets $75.8M · Shareholders' equity $42.4M
- Revenue
- $17.9M
- Operating income
- $1.7M
- Net income
- $2.0M
No dividends on record.
| Institutions108 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 46.73% | 16.39M shares | |
| Insiders8 holders · as of Sep 1, 2026 | 7.22% | 2.53M shares | |
| Strategic holders1 holder · as of Jan 14, 2026 | 7.83% | 2.74M shares | |
| Otherremainder | ≈ 38.22% | 13.40M shares |
35.07M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Rosalind Advisors, Inc.Institution | 9.09% | 3.19M | 13Fas of Jun 30, 2026 |
Southpoint Master Fund, LP1Strategic10 percent owner | 7.83% | 2.74M | 13Gfiled Jan 14, 2026 ↗ |
Sonic Fund II, L.P.Institution | 7.44% | 2.61M | 13Gfiled Feb 17, 2026 ↗ |
Aigh Capital Management LLCInstitution | 7.09% | 2.49M | 13Fas of Jun 30, 2026 |
Orin HirschmanInsider | 5.65% | 1.98M | 13Gfiled Apr 28, 2026 ↗ |
| See all 25 → | |||
- Southpoint Master Fund, LP's own ownership statement (13G, Jan 14, 2026) reports fewer shares than the transaction reports; the statement is used.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 1, 2026 | Rosty Raykov | other: Former Director | −10,000 | $12.11 |
| Aug 31, 2026 | Pierre Sargis Sayad | officer: Chief Medical Officer | −12,000 | $12.18 |
| Aug 27, 2026 | Robert Andrade | officer: CHIEF FINANCIAL OFFICER | −75,000 | $11.78 |
| Aug 3, 2026 | Rosty Raykov | other: Former Director | −10,000 | $9.58 |
| Jul 1, 2026 | Rosty Raykov | other: Former Director | −9,599 | $10.41 |
